Journal: Metabolites

Article Title: Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management

doi: 10.3390/metabo15020127

Figure Lengend Snippet: ( A ) Metabolic syndrome and microbiota: systematic reviews and meta-analyses. ( B ) Probiotics and metabolic syndrome: randomized and non-randomized clinical trials. ( C ) Probiotics and metabolic syndrome: systematic reviews and meta-analyses.

Article Snippet: Wastyk HC et al. [ ] , Randomized controlled trial , 39 adults with elevated Met-S parameters, 23 assigned to the intervention arm, 16 to placebo , Probiotic made of a blend of Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM , 18 weeks , Evaluate the effects of the use of probiotics by themselves to lower Met-S parameters , No significant effects on any of the parameters considered. Data possibly explained by there being responders and non-responders. , Hypothesis of some individuals responding to treatments with probiotics while others being resistant to it could be considered. , High.

Techniques: Probiotics, Clinical Proteomics, Expressing, Activation Assay, Transplantation Assay, Permeability, Concentration Assay, Control

Journal: Metabolites

Article Title: Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management

doi: 10.3390/metabo15020127

Figure Lengend Snippet: ( A ) Diabetes and microbiota: randomized and non-randomized controlled trials. ( B ) Diabetes and microbiota: systematic reviews and meta-analyses. ( C ) Probiotics and diabetes: randomized and non-randomized clinical trials. ( D ) Probiotics and diabetes: systematic reviews and meta-analyses.

Article Snippet: Wastyk HC et al. [ ] , Randomized controlled trial , 39 adults with elevated Met-S parameters, 23 assigned to the intervention arm, 16 to placebo , Probiotic made of a blend of Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM , 18 weeks , Evaluate the effects of the use of probiotics by themselves to lower Met-S parameters , No significant effects on any of the parameters considered. Data possibly explained by there being responders and non-responders. , Hypothesis of some individuals responding to treatments with probiotics while others being resistant to it could be considered. , High.

Techniques: Probiotics, Clinical Proteomics, Sequencing, Control, Expressing, Immunohistochemical staining, Bacteria, Next-Generation Sequencing, Software, Gas Chromatography, Mass Spectrometry, Functional Assay, Comparison, Concentration Assay, Permeability, Produced

Journal: Metabolites

Article Title: Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management

doi: 10.3390/metabo15020127

Figure Lengend Snippet: ( A ) Obesity and microbiota: randomized and non-randomized controlled trials. ( B ) Probiotics and obesity: randomized and non-randomized clinical trials. ( C ) Probiotics and obesity: systematic reviews and meta-analyses.

Article Snippet: Wastyk HC et al. [ ] , Randomized controlled trial , 39 adults with elevated Met-S parameters, 23 assigned to the intervention arm, 16 to placebo , Probiotic made of a blend of Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM , 18 weeks , Evaluate the effects of the use of probiotics by themselves to lower Met-S parameters , No significant effects on any of the parameters considered. Data possibly explained by there being responders and non-responders. , Hypothesis of some individuals responding to treatments with probiotics while others being resistant to it could be considered. , High.

Techniques: Probiotics, Clinical Proteomics, Sequencing, Preserving, Control, Real-time Polymerase Chain Reaction, Gas Chromatography, Bacteria, Capsules, Concentration Assay, Formulation, Computed Tomography, Gene Expression, Expressing, Activity Assay

Journal: Metabolites

Article Title: Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management

doi: 10.3390/metabo15020127

Figure Lengend Snippet: ( A ) Hyperhomocysteinemia and microbiota: systematic reviews and meta-analysis. ( B ) Probiotics and hyperhomocysteinemia: randomized and non-randomized clinical trials.

Article Snippet: Wastyk HC et al. [ ] , Randomized controlled trial , 39 adults with elevated Met-S parameters, 23 assigned to the intervention arm, 16 to placebo , Probiotic made of a blend of Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM , 18 weeks , Evaluate the effects of the use of probiotics by themselves to lower Met-S parameters , No significant effects on any of the parameters considered. Data possibly explained by there being responders and non-responders. , Hypothesis of some individuals responding to treatments with probiotics while others being resistant to it could be considered. , High.

Techniques: Probiotics, Clinical Proteomics, Concentration Assay

Journal: Metabolites

Article Title: Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management

doi: 10.3390/metabo15020127

Figure Lengend Snippet: ( A ) Dyslipidemia and microbiota: randomized and non-randomized controlled trials. ( B ) Dyslipidemia and microbiota: systematic reviews and meta-analyses. ( C ) Probiotics and dyslipidemia: randomized and non-randomized clinical trials. ( D ) Probiotics and dyslipidemia: systematic reviews and meta-analyses.

Article Snippet: Wastyk HC et al. [ ] , Randomized controlled trial , 39 adults with elevated Met-S parameters, 23 assigned to the intervention arm, 16 to placebo , Probiotic made of a blend of Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM , 18 weeks , Evaluate the effects of the use of probiotics by themselves to lower Met-S parameters , No significant effects on any of the parameters considered. Data possibly explained by there being responders and non-responders. , Hypothesis of some individuals responding to treatments with probiotics while others being resistant to it could be considered. , High.

Techniques: Probiotics, Clinical Proteomics, Bacteria, Control, Activity Assay, Concentration Assay

Journal: Metabolites

Article Title: Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management

doi: 10.3390/metabo15020127

Figure Lengend Snippet: ( A ) Sarcopenia and microbiota: randomized and non-randomized controlled trials. ( B ) Probiotics and sarcopenia: randomized and non-randomized clinical trials. The upward arrow (↑) denotes an increase, whereas the downward arrow (↓) denotes a decrease.

Article Snippet: Wastyk HC et al. [ ] , Randomized controlled trial , 39 adults with elevated Met-S parameters, 23 assigned to the intervention arm, 16 to placebo , Probiotic made of a blend of Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM , 18 weeks , Evaluate the effects of the use of probiotics by themselves to lower Met-S parameters , No significant effects on any of the parameters considered. Data possibly explained by there being responders and non-responders. , Hypothesis of some individuals responding to treatments with probiotics while others being resistant to it could be considered. , High.

Techniques: Probiotics, Clinical Proteomics, Shotgun Sequencing, Sequencing, Fat

Journal: Journal of Perinatology

Article Title: Contemporary use of prophylactic probiotics in NICUs in the United States: a survey update

doi: 10.1038/s41372-024-01952-0

Figure Lengend Snippet: Characterization of prophylactic probiotic use in US NICUs.

Article Snippet: Further, an FDA warning to Abbott Laboratories on October 24, 2023 led to discontinued sales of Similac ® Probiotic Tri-Blend.

Techniques: Probiotics

Journal: Journal of Perinatology

Article Title: Contemporary use of prophylactic probiotics in NICUs in the United States: a survey update

doi: 10.1038/s41372-024-01952-0

Figure Lengend Snippet: Characterization of opinions towards AAP probiotic statement and an FDA-approved probiotic formulation.

Article Snippet: Further, an FDA warning to Abbott Laboratories on October 24, 2023 led to discontinued sales of Similac ® Probiotic Tri-Blend.

Techniques: Formulation, Probiotics

Journal: Microbiome Research Reports

Article Title: Probiotics, prebiotics, synbiotics and other microbiome-based innovative therapeutics to mitigate obesity and enhance longevity via the gut-brain axis

doi: 10.20517/mrr.2024.05

Figure Lengend Snippet: Recent double-blinded randomized controlled clinical trials on probiotic therapies for obesity and aging

Article Snippet: A microencapsulated probiotic blend ( L. rhamnosus NCIMB 6375, L. plantarum NCIMB 8826 and L. fermentum NCIMB 5221) was also studied for its effects on HFD-induced MetS hamsters and resulted in favorable alterations to the gut microbiota through decreasing the F/B ratio [ ] .

Techniques: Clinical Proteomics, Reflux